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ABSTRACT
Minimally invasive glaucoma surgery (MIGS)
has been gaining popularity over the last
decade. Although there is no strict definition
for MIGS, all the new procedures share the
common theme of intraocular pressure
reduction with minimal tissue destruction,
short surgical time, simple instrumentation
and fast postoperative recovery. The use of
glaucoma drainage implants has long been the
traditional treatment for complex glaucoma,
but a new wave of glaucoma micro-stents are
now being manufactured with various materials
designed to increase aqueous outflow via
different channels. This review summarises the
current published literature on these devices,
including Sclemm’s canal stents (iStent,
Hydrus), Suprachoroidal stents (CyPass, iStent
supra), and subconjunctival stents (Xen,
Innfocus).
Keywords: Glaucoma; Micro-stents; Minimally
invasive glaucoma surgery
INTRODUCTION
Over the last decade there has been significant
activity in developing novel surgical treatments
for glaucoma. These techniques and devices
embrace the common theme of not only being
effective in reducing intraocular pressure (IOP)
and medication burden but also in causing as
little trauma as possible to the target tissue, and
most importantly they are safe. There is interest
in finding surgical options that reduce surgical
time, have an easily reproducible technique,
and which are accessible to all ophthalmologists
who manage glaucoma patients, rather than
being the preserve of glaucoma specialists.
The term ‘‘minimally invasive glaucoma
surgery’’ (MIGS) has arisen to describe such
procedures; however, there is no widely
accepted definition of MIGS, and thus no
consensus on which specific procedures the
term encompasses.
There has been particular interest recently in
developing tubular stents, comprised of various
materials, which can lower pressure in a similar
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manner to existing glaucoma drainage devices,
but without the associated risks or the
time-consuming and involved surgical
procedure. Such new aqueous drainage devices
can be classified on the basis of the targeted
aqueous outflow pathway: via Schlemm’s canal,
via the suprachoroidal space, or via the
subconjunctival space.
In this article we will describe the principle
current glaucoma micro-implants, the currently
available evidence underpinning their use, and
how they may fit into future practice.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
TRABECULAR MESHWORK BYPASS
Aqueous outflow resistance largely determines
IOP, and the majority of this resistance is
generated between the juxtacanalicular
connective tissue and the inner wall of
Schlemm’s canal. Bypassing this region is,
therefore, a viable method of decreasing IOP.
iStent
The iStent (Glaukos Corporation, Laguna Hills,
CA, USA) is a heparin-coated non-ferromagnetic
titanium device (Fig. 1). It is placed ab interno
through the trabecular meshwork into
Schlemm’s canal under gonioscopic view using
a single-use injector. In the 15 years since its
initial development, a substantial number of
publications have looked at its efficacy as a
single and multiple standalone device, and in
combination with cataract surgery.
The randomised controlled trial (RCT) carried
out by the iStent study group is the largest RCT
to date. This compared the results of cataract
surgery combined with a single iStent to those of
cataract surgery alone in 240 patients. A
statistically significant 72% of participants that
received combination surgery maintained an
IOP B21 mmHg at 12 months [1], and 61% at
24 months [2], compared to 50% at both time
points in the control group that only underwent
cataract surgery. The secondary outcome of a
C20% reduction in IOP was achieved by 66% of
the experimental group at 12 months and 53%
at 24 months, compared to 48 and 44% in the
control group. The mean IOP reduction was
8.4 ± 3.6 mmHg in the treatment group at 12
and 24 months post op.
Medication reduction is another benefit of
this procedure. The mean decrease in
medications compared to screening in this
trial was greater in the treatment group
(1.4 ± 0.8 mmHg) versus the control group
(1.0 ± 0.8) at 12 months (P = 0.005). This is
significant not only for the patients’
convenience and compliance, but importantly
for the protection of their ocular surface and for
the potential success of future drainage surgery.
The reduction in ocular hypotensives was still
numerically larger at 24 months in favour of the
stent group, although no longer statistically
significant. In the stent group, 15% were
receiving medications at month 12, compared
to 35% of the cataract only group (P = 0.001).
Fig. 1 Clinical picture of an iStent implanted in the angle
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A smaller independent RCT by Fea et al.
produced similar results with longer follow up
[3]. After medication washout at 16 months, the
mean IOP in the combined stent and cataract
surgery group was significantly lower than in
the cataract-only group (16.6 ± 3.1 vs
19.2 ± 3.5 mmHg, P = 0.042). This supports
the hypothesis that the reduction in pressure
seen with iStent implantation at the time of
cataract surgery is not the result of the cataract
surgery alone. This significant difference
persisted at 48 months [4] (17.5 ± 2.3 vs
20.4 ± 3.2 mmHg, P = 0.02), demonstrating
the prolonged effect of the stent. There was
also a significant mediation reduction in both
groups, but the difference between the two
treatment groups did not reach statistical
significance.
The use of iStents has not been limited to
ocular hypertension and mild open-angle
glaucoma [5]. Neuhann [6] published a case
series of 62 eyes that included moderate to
advanced glaucoma, and also patients with
previous glaucoma surgery in that eye. The
outcomes in the previous surgery group were
good, although the lower target pressure needed
for their more advanced glaucoma resulted in a
higher medication burden than the group
having no previous surgery. At month 36,
mean IOP in the group with prior glaucoma
surgery was 14.2 ± 2.3 mm Hg, with 44% of
eyes on medications. In the group with no prior
glaucoma surgery, mean IOP at month 36 was
15.4 ± 2.2 mmHg, with only 13% of eyes
receiving medications.
Anatomical studies have shown that
Schlemm’s canal anatomy changes at higher
pressures in normal eyes, with areas of partial
collapse, and that this is exaggerated in primary
open-angle glaucoma (POAG) eyes [7]. It is
therefore possible that even if an iStent is
correctly positioned in Schlemm’s canal, the
flow of aqueous humor to a collector channel
may be restricted. Several studies have looked at
the insertion of multiple iStents, which would
both increase the flow of aqueous humor into
Schlemm’s canal by bypassing the trabecular
meshwork in more regions, and increase the
likelihood of ingress near a collector channel
[8].
Belovay et al. published a case series of 53
eyes with two or three iStents inserted at the
time of cataract surgery. They did not show a
difference in IOP reduction between the two
groups, but did show a significant difference in
the mean number of postoperative medications
[9]. A recent study by Katz et al. published a
prospective study of 119 patients randomized to
one, two, or three iStents. All but one of these
patients was phakic, and the procedure was not
combined with cataract surgery. At 18 months,
mean unmedicated IOP was 15.9 ± 0.9 mmHg
in one-stent subjects, 14.1 ± 1.0 mmHg in
two-stent subjects, and 12.2 ± 1.1 mmHg in
three-stent subjects. Intraocular pressure
reduction was significantly greater with
implantation of each additional stent
(P\0.001) [10].
With the view that multiple stents appear to
be superior, Glaukos have manufactured a
second-generation iStent, termed the iStent
Inject. The single-use injector is designed to be
used left- or right-handed, and comes
pre-loaded with two stents. The stents are
designed to be ‘‘bullet’’ rather than L-shaped.
Initial laboratory studies confirmed that this
device increased outflow facility [11]. In clinical
use, insertion of two iStent Injects alone had the
same efficacy as adding a second-line
medication in patients uncontrolled on one
medication [12]. Voskanyan et al. further
demonstrated that in patients with IOP not
controlled on two medications, two iStent
Injects alone produced an IOP B18 mmHg
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without medications in 66% of subjects at
12 months [13].
The safety profile with this procedure
appears to be excellent, with no major
complications reported in the literature.
Hydrus
The Hydrus Microstent (Ivantis Inc, Irvine, CA,
USA) is a trabecular bypass device and
Schlemm’s canal scaffold (Fig. 2). It is
manufactured from nitinol, an alloy of nickel
and titanium. It is an 8-mm-long crescent with
an open posterior surface and three windows in
the anterior surface, designed to be inserted
through trabecular meshwork and to follow the
curve of Schlemm’s canal. The length, being
larger than the iStent, is such that three clock
hours of Schlemm’s canal can be cannulated,
increasing the likelihood of accessing multiple
collector channels, as well as dilating the canal
and preventing canal compression. Increased
outflow facility was demonstrated ex vivo and
was twice as much as with double iStents [14].
Electron microscopy demonstrated no visible
damage to the trabecular meshwork despite the
size of the device [15].
Clinical results were published in 2012 by
Pfeiffer et al. where 100 eyes were randomised
to cataract surgery alone or cataract surgery plus
Hydrus. At 24 months the proportion of
patients using no hypotensive medications
was significantly higher in the Hydrus plus
cataract surgery group [16] (73 vs. 38%;
P = 0.0008). The primary endpoint of a 20%
reduction in washed-out diurnal IOP compared
to baseline was achieved in a significantly
higher proportion of Hydrus patients than
with cataract surgery alone (80 vs. 46%;
P = 0.0008). The washed-out diurnal IOP at
24 months was also significantly lower in the
Hydrus patients (16.9 ± 3.3 vs.
19.2 ± 4.7 mmHg; P = 0.0093). Other studies
directly comparing Hydrus with iStents are
currently underway and results will likely be
available in 1–2 years [17, 18].
SUPRACHOROIDAL SPACE
The suprachoroidal space is an intriguing target
for the development of new procedures. There
are several reasons to suppose that targeting this
pathway might be successful. Firstly, the most
effective topical hypotensive medications, the
prostaglandins, exert their effect via this
pathway [19]. Secondly, it is known that there
is a negative pressure gradient that drives
aqueous humor in the direction of the
suprachoroidal space [20]. Thirdly, it has long
been known that producing a cyclodialysis cleft
lowers the pressure [21]. Consequently, there
have been numerous attempts to develop a
surgical technique to exploit this possibility. It
had previously proven difficult to find a safe
and accessible surgical technique that produces
stable long-term results without the hypotony
and rebound high pressure associated with
cyclodialysis.
Fig. 2 Clinical picture of Hydrus stent implanted into
Schlemm’s canal
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Cypass
The Cypass (Transcend Medical, Menlo Park,
CA, USA) is a fenestrated polyamide tube
6.35 mm in length, with a 300-mm lumen. It
is designed to be implanted ab interno and
inserted between the ciliary body and the sclera.
It provides a direct communication between the
anterior chamber and suprachoroidal space.
The first published study on Cypass looked at
its efficacy when combined with cataract surgery
in two groups of patients [22]. Cohort 1 had
uncontrolled open-angle glaucoma
(IOP C 21 mmHg). Cohort 2 consisted of
patients whose glaucoma was controlled, but
who wished to reduce their drop dependence.
Two-year data showed a 37% reduction in IOP in
the uncontrolled glaucoma group with a mean
number of medications decreasing from 2.2 at
baseline to 1.0 [23]. Similarly, the controlled
glaucoma group showed a reduction in
medications from 2.2 to 1.0. No
sight-threatening adverse events occurred.
Transient hypotony occurred in 15.4% of eyes
and micro-stent obstruction due to iris tissue
overgrowth in 8.8% [24]. Fifteen subjects (11%)
required secondary incisional glaucoma surgery.
When a Cypass stent was inserted alone in
patients who were not controlled on glaucoma
medications, 83% of them avoided further
glaucoma surgery [25]. Mean IOP was reduced
by 35% to 16.4 ± 5.5 mmHg at 12 months
(P\0.0001) and mean medication usage
decreased by 36% (P = 0.002). There were no
serious adverse events. Seven patients were
reported as having pressure rises [30 mmHg.
There was no hypotony lasting more than
4 weeks postoperatively and no hypotonous
maculopathy.
The COMPASS study is a prospective,
multicentre, randomised controlled trial
conducted at 27 sites in the United States. The
patients have been randomised to receive either
the Cypass Micro-Stent during cataract surgery
or to undergo cataract surgery alone. More than
500 patients have been randomised so far, but
no results have been published to date.
The iStent Supra
iStent Supra (Glaukos Corporation, Laguna
Hills, CA, USA) is a 4-mm tube made of
polyethersulfone and titanium (Fig. 3). The
concept and mode of delivery is almost
identical to the Cypass. There are currently no
published studies on surgical outcomes,
although preliminary results presented in
scientific meetings have demonstrated
promising results.
SUBCONJUNCTIVAL SPACE
The subconjunctival space is the traditional
outflow pathway for glaucoma drainage
surgery. Successful surgery depends on the
continued patency of a pathway for aqueous
humor, and on the scarring response in the
conjunctiva (Fig. 4).
XEN GEL Implant
The XEN GEL Implant (AqueSys Inc., Aliso
Viejo, CA, USA) is a 6-mm cylinder of
Fig. 3 Anterior segment OCT image of an iStent Supra
in situ with ﬂuid in the suprachoroidal space
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collagen-derived gelatin cross-linked with
glutaraldehyde, making it permanent and
non-degrading, with no foreign body reaction.
It comes pre-loaded in the injector and is
implanted ab interno, creating a drainage
pathway between the anterior chamber and
subconjunctival space. The procedure is often
augmented with subconjunctival injection of
mitomycin-C. Long-term animal studies have
shown the Xen implant structure to be
stable over several years [26]. It softens on
contact with water within 1–2 min, meaning
that it can bend and conform to tissue, reducing
the risk of erosion. Microforce testing has
shown the XEN 45 to be more than 100 times
as flexible as a typical silicone shunt tube [27].
Although initially produced with three
different lumen diameters, the tube with the
45-nm lumen size is the only device now
recommended for implantation by the
manufacturer. This lumen size was chosen in
an effort to design a device with the necessary
dimensions to prevent postoperative hypotony
by the primary flow resistance of the tube itself
[28]. The tube length of 6 mm was identified as
the ideal length for passage ab interno from the
trabecular meshwork to the subconjunctival
space at an optimal distance from the limbus.
The Hagen-Poiseuille equation was then used to
calculate the required internal dimensions of a
tube that would prevent hypotony at average
aqueous humour production of 2–3 lL/min by
providing a steady-state pressure of
approximately 6–8 mmHg. Implants of larger
lumen size rely on conjunctival resistance to
prevent hypotony, and as conjunctival
resistance is low in the immediate
postoperative period, the risk of hypotony
with larger lumen tube stents is greatest at
that time.
Little published data exists so far on the XEN
45 implant. A pilot study published in 2015 on
cataract surgery combined with a XEN 63
(63 nm lumen) or XEN 140 (140 nm lumen)
[29] showed a reduction of IOP from 22.4 (±4.2)
mmHg to 15.4 (±3.0) mmHg at 12 months
postoperatively (P\0.0001). The number of
medication classes reduced from 2.5 ± 1.4 to
0.9 ± 1.0.
In another pilot study on XEN 140 insertion
as a standalone procedure [30] in 49 eyes, 40%
of patients had an outcome classified as an
unqualified success at 12 months, achieving an
IOP B18 mmHg and C20% reduction in IOP,
with 89% being successful when those on
medications were included, despite a high
proportion of patients having had a previous
failed trabeculectomy.
These studies are not directly comparable to
the currently recommended device and
technique, however. As well as having larger
lumen size, neither study used subconjunctival
mitomycin C at the time of implant insertion.
This is likely to have affected the degree of
scarring, and therefore the outcome in terms of
pressure, due to increased conjunctival
resistance, and also the number of
postoperative needling interventions required.
There were no serious adverse events
attributed to the device in either study. At
Fig. 4 Colour photo showing a Xen implant subconjunc-
tivally in the superior nasal quadrant
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12 months there were no cases of device
erosion, despite the implants used having
greater stiffness than the XEN 45. There were
no cases of prolonged hypotony, although
several patients in both studies required
injection of ophthalmic viscoelastic device in
the anterior chamber, more so with the 140-nm
lumen tube.
The current Xen 45 is undergoing its phase 4
trial, and results should be available in 1–2 years
time. Data was presented at ASCRS in 2015 on
31 patients with open-angle glaucoma, who
required surgical treatment for glaucoma and
cataracts, and who underwent implantation of
the XEN 45 with MMC combined with
phacoemulsification. The mean preoperative
IOP was 20.8 ± 4.6 mmHg. The mean
postoperative IOPs were 13.1 ± 3.6 mmHg at
12 months (p\0.001) [31]. Mean number of
preoperative medications was 2.7 ± 1, and this
reduced to 0.9 ± 1.1 (p\0.001) at 12 months.
There were no complications.
InnFocus
The InnFocus Microshunt (InnFocus Inc,
Miami, FL, USA), formerly known as the MIDI
Arrow, is an aqueous drainage shunt designed
to be implanted ab externo. As a fornix-based
conjunctival flap and dissection of a shallow
scleral pocket is required, unlike the other
devices covered in this review, it resembles
conventional trabeculectomy more than MIGS.
Of interest, however is the product’s material
construction. The Microshunt is constructed
from a material (Poly Styrene-block-
IsoButylene-block-Styrene or SIBS) developed
by the device’s inventors specifically for
medical implants. It is a
biostable thermoplastic elastomer with some
of the properties of silicone rubber and
polyurethane [32]. It has enhanced
biocompatibility and long-term stability with
less inflammatory reaction than with
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Fig. 5 Comparison of the pressure-lowering effect of (1) combined phacoemulsiﬁcation and iStent [2], (2) combined
phacoemulsiﬁcation and Hydrus [16], (3) CyPass alone [25], (4) XEN 45 alone [31], and (5) InnFocus alone [33]
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to less postoperative conjunctival fibrosis.
During development, however, it was found
that the fins designed to prevent tube migration
could erode through the conjunctiva—hence,
the need for a scleral pocket.
A study of 23 eyes with Microshunt insertion,
some with and some without cataract surgery,
showed that over 80% of the patients had had an
IOP B14 mmHg at 3 years [33]. At 3 years, the
number of medications had fallen from
2.6 ± 0.9 to 0.8 ± 1.2 in the eyes with
Microshunt alone, and from 2.0 ± 0.9 to
0.4 ± 0.1 in the eyes that underwent a
combined procedure. In the group as a whole,
the mean IOP at 3 years was 10.7 ± 3.5 mmHg
and the qualified success rate (IOP B14 mmHg
and IOP reduction C20%) was 95%. The most
common complications were transient
hypotony (13%) and transient choroidal
effusion (8.7%), which all resolved
spontaneously. There were no leaks, infections,
migrations, erosions, persistent corneal oedema,
or serious long-term adverse events.
Figures 5 and 6 summarise the pre and
postoperative IOP and medications for each
device using the most representative series.
DISCUSSION
The large number of new glaucoma drainage
devices emerging in recent years is a testament
to both the desire to find a safe and simple
surgical procedure to treat mild to moderate
glaucoma, and also to the inability of any one
procedure to establish itself as filling this need.
Studies comparing a single iStent inserted at
the time of cataract surgery to cataract surgery
alone showed statistically significant but
relatively modest additional reductions in
pressure. The reduction in the number of
medications is beneficial, however, and is
more promising for the iStent finding a place
in clinical practice given the ease of application.
There are also new roles found for iStent use in
other ways than as simply an adjunct to cataract
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Fig. 6 Comparison of the reduction in number of
medications following (1) combined phacoemulsiﬁcation
and iStent [2], (2) combined phacoemulsiﬁcation and
Hydrus [16], (3) CyPass alone [25], (4) XEN 45 alone
[31], and (5) InnFocus alone [33]
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use as a standalone device, as well as in cases of
secondary glaucoma and following failed
drainage surgery.
Multiple stents show more encouraging
results in lowering pressure, and the
new-generation device with multiple
pre-loaded stents makes this easier. This would
increase the cost of the procedure, however, and
there is a real lack of data currently regarding
the cost effectiveness of all these new devices.
The Hydrus Microstent theoretically has a
better probability of improving the anatomical
outflow pathway than the iStent, being larger
and longer, and this appears to be borne out by
laboratory results. So far the published clinical
results look similar to those of the iStents, with
a potentially better outcome at 2 years. The
outcome of the Hydrus vs iStent studies should
answer whether the results of laboratory studies
suggesting greater efficacy than two iStents can
be replicated in vivo.
Currently, there is particular interest in the
XEN Gel Implant due to the potentially greater
pressure lowering effect compared to other
outflow pathways. There is, however, a
correspondingly greater degree of
postoperative management required compared
to an ‘‘insert and forget’’ trabecular meshwork or
supracilliary stent. It remains to be seen
whether this additional workload is made
worthwhile by its efficacy, and whether the
greater simplicity and safety profile outbalances
the established efficacy of traditional drainage
surgery.
As efficacy and safety data emerges, before
judging procedures against current practice,
care must be taken in deciding which
treatments to compare against one another. A
modest treatment effect may be sufficient to
justify a procedure if the risk profile is low
enough. The treatment effect of selective laser
trabeculoplasty is comparable to monotherapy
with a prostaglandin analogue [34], and that is
not considered an impediment to its use as an
intervention. In many cases a modest additional
effect is all that is needed to reduce a patient’s
risk to what we deem to be acceptable for their
circumstances, and we regularly use this as a
justification for adding a third or fourth
medication to a patient’s regimen.
A CyPass stent is unlikely to match the
pressure-lowering effect of a trabeculectomy,
but it may prove to be the equivalent of more
than one drop. Given the widely recognised
dissatisfaction and disadvantages with
long-term drop therapy, the benefit from this
should not be underestimated. These
disadvantages are tolerated, by
ophthalmologists at least, because of the
relative safety of drops, but in many cases a
patient might decide to accept a slightly higher
risk profile to reduce or eliminate their drops.
Further work will need to be done on
patient-reported outcomes as well as on
clinical effectiveness.
Similarly, subconjunctival drainage
microstents should not be considered a direct
replacement for traditional drainage surgery, as
they do not appear to be able to achieve the
lower target pressures needed for some patients,
but the safety profile may prove to be such that
a XEN implant is justifiable in a patient for
whom a trabeculectomy was not, and not all
patients need a pressure of 10 mmHg.
Another consideration that will certainly
influence the uptake of new procedures is their
economic benefit. In an economic analysis of
iStent use in the Canadian medical system [35],
cost savings of Can$20.77, Can$1,272.55, and
Can$2,124.71 per patient were estimated over
6 years, when comparing two iStents versus
mono-, bi-, and triple therapy, respectively.
Two stents plus one medication still showed
savings over two or three drops. In the CyPass
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study described above, 83% of uncontrolled
patients did not require trabeculectomy after
CyPass insertion as a standalone procedure.
This is likely to be associated with significant
savings in theatre time and follow-up
appointments, and similar savings have been
discussed with the use of subconjunctival space
stents. Nonetheless data to support the above
does not currently exist in the literature.
CONCLUSION
The rapid influx of new devices onto the market
in recent years has caused some to wonder
whether we are entering a new era of microstent
surgery in glaucoma management. The results
of large prospective randomised studies are still
awaited for many of the most promising
devices. It will be interesting to see whether
the ‘‘trabeculectomy holiday’’ that followed the
introduction of prostaglandin analogues is
repeated. It is more likely that, rather than
replacing older treatments, new treatments will
find their own niche depending on their
respective risks and benefits. This has always
been the case and the process of technological
advance is on-going, bringing new treatments
to challenge those discussed above. Future
developments, such as the anticipated
drug-eluting implants, will rekindle the debate.
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